FEB 11, 2016 3:22 PM PST

Treating TTP with Synthetic Antibodies

WRITTEN BY: Kara Marker
Rare but deadly, thrombotic thrombocytopenic purpura (TTP) is a disease where blood clots block the smallest blood vessels often leading to kidney failure, stroke, and heart disease. Over 4 million Americans are affected each year, either from hereditary or acquired forms of the disease.
 
Past the acute phase, TTP is relatively easily defeated with immunotherapy, said Paul Knöbl from the Medical University of Vienna. However, 10 to 20 percent of people do not survive the acute phase, even with plasma exchange therapy. In a new study published in the New England Journal of Medicine, Knöbl and other researchers from the Medical University of Vienna examined the capability of a synthesized antibody to reverse the impact of the disease.
 
Newly formed blood vessel within an occluded artery of the lower leg

 
TTP is characterized by a deficiency of an enzyme called ADAMST13 regardless of whether the disease was acquired or inherited. Without ADAMST13, another protein called von Willebrand is overexpressed and destructively so, binding platelets and inducing aggregation in blood vessels. Blood clots caused by TTP can lead to kidney failure, stroke, and heart disease.
 
Current plasma exchange therapy removes autoantibodies causing the ADAMST13 deficiency, removes overgrown von Willebrand protein complexes, and replenishes the body’s stock of ADAMST13. After a patient survives the acute phase, immunotherapy prevents continuous autoantibody formation. The synthesized antibody proposed by this study would be used for treatment both during and after the acute phase, instead targeting the masses of overactive von Willebrand protein. By blocking the protein’s interaction with platelets, the antibody reduces the severity of blood clots characterizing TTP to practically zero.
 
"In future this drug might also be used to treat similar diseases, which are jointly caused by overactivity of the von Willebrand factor, and therefore represents a new treatment option," said the Medical University of Vienna’s Bernd Jilma.
 
The antibody being studied is called “caplacizumab.”
 

Source: Medical University of Vienna, New England Journal of Medicine
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 16, 2020
Cardiology
Stem Cells Can Generate a 3D Mini-Model of the Heart
SEP 16, 2020
Stem Cells Can Generate a 3D Mini-Model of the Heart
The heart is a special organ, and while we know a lot about how it develops, there are still mysteries.
OCT 13, 2020
Cardiology
A Kidney Toxin Could Act as a Biomarker for Cardiovascular Risk
OCT 13, 2020
A Kidney Toxin Could Act as a Biomarker for Cardiovascular Risk
Biomarkers have taken the diagnostic field by storm over the past decade. The search for stable, easy to access indicato ...
NOV 03, 2020
Cardiology
A New Peptide Could Help Repair and Protect the Heart During Ischemia Reperfusion Injury
NOV 03, 2020
A New Peptide Could Help Repair and Protect the Heart During Ischemia Reperfusion Injury
Cardiovascular disease is one of the most common causes of death in the world. Although we have many treatments against ...
NOV 26, 2020
Cardiology
Possible Cardioprotective Effects of the Diabetes Drug Empagliflozin
NOV 26, 2020
Possible Cardioprotective Effects of the Diabetes Drug Empagliflozin
Cardiovascular disease and diabetes are often associated with each other, as many issues caused by diabetes promote hear ...
DEC 13, 2020
Cardiology
Potential Treatment for Common Cause of Heart Disease is ID'ed
DEC 13, 2020
Potential Treatment for Common Cause of Heart Disease is ID'ed
The most common cause of heart disease in elderly people is calcific aortic valve disease, in which calcium builds up in ...
JAN 19, 2021
Cardiology
Risk of Atrial Fibrillation Raised by Daily Alcoholic Drink
JAN 19, 2021
Risk of Atrial Fibrillation Raised by Daily Alcoholic Drink
Some studies have suggested that moderate alcohol intake is linked to a lower risk of death from heart disease. But that ...
Loading Comments...